Zobrazeno 1 - 10
of 93
pro vyhledávání: '"Ann M. Mauer"'
Autor:
Linda Sutton, Lynn G. Dressler, Patricia A. Kartcheske, Julie R. Gralow, Aminah Jatoi, Ronald D. Hart, Heshan Liu, Maria Theodoulou, Alice B. Kornblith, C. Cirrincione, Barbara A. Parker, Ann M. Mauer, Edith A. Perez, Ahmad A. Mahmood, Arti Hurria, Mei Yin C. Polley, Debjani Grenier, Donald A. Berry, Lisa A. Carey, Larry Norton, Hyman B. Muss, Clifford A. Hudis, Gustav Magrinat, Harold J. Burstein, Harvey J. Cohen, Eric P. Winer, Ann H. Partridge, Antonio C. Wolff
PURPOSE Older women with breast cancer remain under-represented in clinical trials. The Cancer and Leukemia Group B 49907 trial focused on women age 65 years and older. We previously reported the primary analysis after a median follow-up of 2.4 years
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e78d83708f8da175563c5bd878d26f78
https://europepmc.org/articles/PMC6900836/
https://europepmc.org/articles/PMC6900836/
Autor:
Stanislav Spelda, Andrew Coates, Barry L. Dowell, Andrew Krivoshik, Jane Qian, Peter Ansell, Xiangdong Zhou, Gary S. Gordon, Rajendra S. Pradhan, Ann M. Mauer, Martin Šmakal, Evelyn McKeegan, Rosalyn A. Juergens, Charles M. Rudin, Michael S. Wertheim
Publikováno v:
Journal of Clinical Oncology. 29:1075-1082
Purpose ABT-751 is an antimitotic and vascular disrupting agent with potent preclinical anticancer activity. We conducted a phase I and randomized double-blind phase II study of pemetrexed with ABT-751 or placebo in patients with recurrent advanced o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92882bc9bc37b39ddf5c47974e8889d2
https://doi.org/10.1200/jco.2010.32.5944
https://doi.org/10.1200/jco.2010.32.5944
Autor:
Mark K. Ferguson, David F. Sciortino, Everett E. Vokes, Masha Kocherginsky, Kenneth A. Kesler, Daniel Haraf, Livia Szeto, Paul A. S. Fishkin, Ann M. Mauer, Rafat Ansari, Philip C. Hoffman, Nicholas W. Choong, James L. Wade, Alan Sandler, Mitchell C. Posner, Stuart A. Krauss
Publikováno v:
Medical Oncology. 28:152-161
We performed a phase II trial to evaluate a docetaxel-based regimen in locoregionally advanced esophageal cancer. Untreated stage II-IVa esophageal cancer patients with performance status 0-2 were included. Tumor resectability was determined prior to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5c6657bd024322ac8844e432c8568d8
https://doi.org/10.1007/s12032-010-9658-1
https://doi.org/10.1007/s12032-010-9658-1
Autor:
Thomas E, Stinchcombe, Ann M, Mauer, Lydia D, Hodgson, James E, Herndon, Thomas J, Lynch, Mark R, Green, Everett E, Vokes, John, Leonard
Publikováno v:
Journal of Thoracic Oncology. 3(11):1301-1307
Background Cancer and Leukemia Group B trial 9430 was a randomized phase II trial which investigated the safety and activity of four novel doublets in untreated extensive stage small cell lung cancer. The results of the paclitaxel and cisplatin arm h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5be3067dfee733cf26fd1201d8fc05cc
Autor:
Anne E. Hagey, Gary Gordon, Ann M. Mauer, Mark Kozloff, Jiang Qian, Ezra E.W. Cohen, Lee S. Schwartzberg, Patrick C. Ma, Andrew I. Coates
Publikováno v:
Journal of Thoracic Oncology. 3:631-636
Purpose To determine the tolerability and efficacy of ABT-751, an oral antimitotic agent that inhibits polymerization of microtubules, in patients with advanced taxane-refractory non-small cell lung carcinoma (NSCLC). Patients and Methods Eligibility
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d49b9686f960656dc4c54968cc6422c9
https://doi.org/10.1097/jto.0b013e318174e01f
https://doi.org/10.1097/jto.0b013e318174e01f
Autor:
Nicholas W. Choong, Mark K. Ferguson, Kristen Kasza, Stuart A. Krauss, Daniel J. Haraf, Philip C. Hoffman, Ann M. Mauer, Everett E. Vokes, Charles M. Rudin, Livia Szeto, Peter K. Tothy
Publikováno v:
Journal of Thoracic Oncology. 3:59-67
Background The aim of this study was to determine the maximum tolerated dose (MTD), dose limiting toxicities (DLTs), and determine the phase II dose for the combination of irinotecan-carboplatin-paclitaxel given as induction chemotherapy and with con
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b74dba69216d466a921c19472f92fec3
https://doi.org/10.1097/jto.0b013e31815e8566
https://doi.org/10.1097/jto.0b013e31815e8566
Autor:
Katherine E. Posther, Daniel J. Haraf, Everett E. Vokes, Livia Szeto, Tanguy Y. Seiwert, Binh Nguyen, Ann M. Mauer, Ravi Salgia, Philip C. Hoffman, Christopher George, Philip P. Connell
Publikováno v:
Clinical Cancer Research. 13:515-522
Purpose: The primary objective of this phase I study was to determine the maximum tolerated dose for pemetrexed, alone and in combination with carboplatin, with concurrent radiotherapy.Experimental Design: Patients with locally advanced or metastatic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c6799e2fee18ae7bac79ae1829d5b8a
https://doi.org/10.1158/1078-0432.ccr-06-1058
https://doi.org/10.1158/1078-0432.ccr-06-1058
Autor:
Ezra E.W. Cohen, Ann M. Mauer, Elizabeth A. Blair, Allison Dekker, Kerstin M. Stenson, Daniel J. Haraf, Everett E. Vokes, Tanguy Y. Seiwert
Publikováno v:
Cancer Investigation. 25:435-444
The purpose of this study was to determine the maximum tolerated dose (MTD) of docetaxel based induction and concomitant chemoradiotherapy (CRT) after using the FHX platform (5 = 5-FU, H = hydroxyurea, X = Radiation). Patients with Stage III/IV local
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8abd06a2b9db6fdabab22b18f6d527ef
https://doi.org/10.1080/07357900701357993
https://doi.org/10.1080/07357900701357993
Autor:
Bhoomi Mehrotra, Everett E. Vokes, Bruce Brockstein, Ann M. Mauer, Marcy A. List, Madeleine A. Kane, Dezheng Huo, Carolyn Pierce, Allison Dekker, Ezra E.W. Cohen
Publikováno v:
Clinical Cancer Research. 11:8418-8424
Purpose: An objective response rate of 11% was reported in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) treated with 500 mg daily gefitinib although the recommended dose in lung cancer is 250 mg. This
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2b89db331775f7cc1c7ed0fa4242a85
https://doi.org/10.1158/1078-0432.ccr-05-1247
https://doi.org/10.1158/1078-0432.ccr-05-1247
Autor:
E. H. Kraut, Everett E. Vokes, Ann M. Mauer, Stuart A. Krauss, Kristen Kasza, Livia Szeto, Rafat Ansari
Publikováno v:
Annals of Oncology. 16:1320-1325
Background: The aim of the study was to evaluate the efficacy and tolerability of the combination of oxaliplatin, fluorouracil and leucovorin in patients with advanced esophagus cancer. Patients and methods: Thirty-five patients with recurrent or met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9403abbece4ffb733e5e8e29fcbbdfe
https://doi.org/10.1093/annonc/mdi249
https://doi.org/10.1093/annonc/mdi249